QUADRANT CAPITAL GROUP LLC - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 166 filers reported holding REVANCE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.1%.

Quarter-by-quarter ownership
QUADRANT CAPITAL GROUP LLC ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,641
-60.7%
143
-13.3%
0.00%
Q2 2023$4,177
-17.9%
165
+4.4%
0.00%
-100.0%
Q1 2023$5,090
+72.3%
158
-1.2%
0.00%
Q4 2022$2,954
-50.8%
160
-25.9%
0.00%
-100.0%
Q3 2022$6,000
+100.0%
2160.0%0.00%
Q2 2022$3,000
-40.0%
216
-16.0%
0.00%
-100.0%
Q1 2022$5,0000.0%257
-18.9%
0.00%0.0%
Q4 2021$5,000
+66.7%
317
+180.5%
0.00%
Q3 2021$3,0000.0%113
+4.6%
0.00%
Q2 2021$3,000
-50.0%
108
-50.5%
0.00%
-100.0%
Q1 2021$6,0000.0%2180.0%0.00%0.0%
Q4 2020$6,000
+20.0%
2180.0%0.00%0.0%
Q3 2020$5,0000.0%2180.0%0.00%0.0%
Q2 2020$5,000
-95.2%
218
-96.9%
0.00%
-94.1%
Q1 2020$104,000
-6.3%
7,020
+0.1%
0.02%
+30.8%
Q4 2019$111,000
+24.7%
7,0110.0%0.01%
-7.1%
Q3 2019$89,000
+287.0%
7,011
+374.4%
0.01%
+250.0%
Q1 2019$23,000
+1050.0%
1,478
+1335.0%
0.00%
+300.0%
Q4 2018$2,0000.0%1030.0%0.00%0.0%
Q3 2018$2,0000.0%1030.0%0.00%0.0%
Q2 2018$2,000
-33.3%
1030.0%0.00%0.0%
Q1 2018$3,0000.0%1030.0%0.00%0.0%
Q4 2017$3,000
+50.0%
1030.0%0.00%0.0%
Q3 2017$2,0000.0%1030.0%0.00%0.0%
Q2 2017$2,0000.0%1030.0%0.00%0.0%
Q1 2017$2,0001030.00%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
NovaQuest Capital Management, L.L.C. 1,558,426$42,779,00061.17%
Essex Woodlands Management, Inc. 3,342,047$91,739,00021.30%
Sio Capital Management, LLC 101,292$2,780,0001.54%
Fosun International Ltd 472,532$12,971,0000.66%
Rhenman & Partners Asset Management AB 203,181$5,577,0000.57%
ArrowMark Colorado Holdings LLC 1,804,275$49,527,0000.46%
ESSEX INVESTMENT MANAGEMENT CO LLC 87,355$2,398,0000.30%
FOX RUN MANAGEMENT, L.L.C. 18,477$507,0000.16%
Phoenix Investment Adviser LLC 2,400$66,0000.12%
Quinn Opportunity Partners LLC 33,100$909,0000.12%
View complete list of REVANCE THERAPEUTICS INC shareholders